GLP-1 drugs linked to major slowdown in breast cancer, prostate cancer and more: new study

Nypost · May 28, 2026 · 544 words · By Fox News

headphones Listen to the eFinder podcast briefing

Ready to play

Daily briefing

What to know about GLP-1 drugs linked to major slowdown in breast cancer, prostate cancer and more: new study

GLP-1 drugs linked to major slowdown in breast cancer, prostate cancer and more: new study See more of our coverage in your search results.

Claims checked 12

Techniques found 0

Topics 0

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center75%

Right25%

4 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

GLP-1 drugs linked to major slowdown in breast cancer, prostate cancer and more: new study See more of our coverage in your search results.

Why it matters

Add The New York Post on GooglePopular glucagon-like peptide-1 (GLP-1) weight-loss drugs may help slow the spread of some cancers, according to new research to be presented at a major medical conference.

Common ground

Research led by Cleveland Clinic found that the medications may reduce the spread of several obesity-related cancers, including lung, breast, colorectal and liver cancers.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

Follow-up questions

What concrete event or decision sits underneath the headline: GLP-1 drugs linked to major slowdown in breast cancer, prostate cancer and more: new study?
What evidence would most clearly confirm or weaken the claim that The findings will be presented at the 2026 ASCO Annual Meeting next week in Chicago?
What should readers watch for in the next update to know whether the story is changing?

open_in_new Read the original article: https://nypost.com/2026/05/28/health/glp-1-drugs-linked-to-major-slowdown-in-can…

fact_checkClaims Checked

eFinder analyzed this article and checked 12 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

info Single Source 4

check_circle Corroborated 3

schedule Pending 2

help Insufficient Evidence 2

verified Verified By Reference 1

info

Claim 1: “The findings will be presented at the 2026 ASCO Annual Meeting next week in Chicago.”

SINGLE SOURCE

The provided evidence for this claim consists of dictionary definitions of the word 'findings' and general research chapters, rather than confirmation of a specific 2026 ASCO meeting presentation. No independent source confirms this specific event date and location.

travel_explore

web search NEUTRAL — 1 day ago · Findings is an interdisciplinary, peer-reviewed, open access journal focused on short, clear, and pointed research results.
https://findingspress.org/

travel_explore

web search NEUTRAL — Something that has been found. 2. a. A conclusion reached after examination or investigation: the finding of a grand jury; a coroner's findings. b. A statement or document containing an authoritative …
https://www.thefreedictionary.com/findings

travel_explore

web search NEUTRAL — Jun 23, 2025 · What Is Results and Findings in Research? Chapter 4, often titled Results and Findings, is the part of your research where you present, analyze, and interpret the data you collected. Th…
https://philscholar.com/results-and-findings/

check_circle

Claim 2: “Half of the participants started a GLP-1 medication – semaglutide, tirzepatide, dulaglutide, liraglutide, lixisenatide or pramlintide – after their cancer diagnosis.”

CORROBORATED

Two independent sources (ASCO and another web result) explicitly list the same set of GLP-1 drugs (liraglutide, pramlintide, dulaglutide, tirzepatide, lixisenatide, semaglutide) and the 50% split in participants.

menu_book

wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists, GLP-1RAs, and informally as simply GLP-1s, are a class of medications that activate the GLP-1 receptor, causing reduced…
https://en.wikipedia.org/wiki/GLP-1_receptor_agonist

menu_book

wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide. It is produced and secreted by int…
https://en.wikipedia.org/wiki/Glucagon-like_peptide-1

menu_book

wikipedia NEUTRAL — The glucagon-like peptide-1 receptor (GLP1R) is a G protein-coupled receptor (GPCR) found on beta cells of the pancreas and on neurons of the brain. It is involved in the control of blood sugar level …
https://en.wikipedia.org/wiki/Glucagon-like_peptide-1_recept…

+ 3 more evidence sources

verified

Claim 3: “The other half began taking a DPP-4 inhibitor comparator “gliptins,” a different class of diabetes medications”

VERIFIED BY REFERENCE

Wikipedia and PMC confirm that DPP-4 inhibitors are known as 'gliptins' and are a different class of diabetes medications used for Type 2 Diabetes, supporting the technical description of the comparator group.

menu_book

wikipedia NEUTRAL — Dipeptidyl peptidase-4 (DPP4 or DPPIV), also known as adenosine deaminase complexing protein 2 or CD26 (cluster of differentiation 26) is a protein that, in humans, is encoded by the DPP4 gene. DPP4 i…
https://en.wikipedia.org/wiki/Dipeptidyl_peptidase-4

menu_book

wikipedia NEUTRAL — Inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins) are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus …
https://en.wikipedia.org/wiki/Dipeptidyl_peptidase-4_inhibit…

menu_book

wikipedia NEUTRAL — Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are enzyme inhibitors that inhibit the enzyme dipeptidyl peptidase-4 (DPP-4). They are used in the treatment of type 2 diabetes mellitus. Inhibitio…
https://en.wikipedia.org/wiki/Discovery_and_development_of_d…

+ 3 more evidence sources

check_circle

Claim 4: “Research led by Cleveland Clinic found that the medications may reduce the spread of several obesity-related cancers, including lung, breast, colorectal and liver cancers.”

CORROBORATED

Multiple independent web sources report that GLP-1 medications may reduce the risk of metastatic progression in lung, breast, colorectal, and liver cancers.

travel_explore

web search NEUTRAL — May 21, 2026 · Studies suggest that GLP-1s may prevent development of certain types of cancer, primarily colorectal and other obesity-related cancers. Although ...
https://www.asco.org/about-asco/press-center/glp-may-reduce-…

travel_explore

web search NEUTRAL — 23 hours ago · ... GLP-1 drugs may reduce metastasis risk in colorectal, liver, breast, and lung cancers. But let's be cautious—more research is needed! For ...
https://www.facebook.com/medscape/posts/yet-another-large-da…

travel_explore

web search NEUTRAL — 5 days ago · ... GLP-1 drugs were 38 to 50 percent less likely to progress to metastatic disease in four cancers: lung, breast, colorectal and liver. One ...
https://www.washingtonpost.com/health/2026/06/03/science-aro…

schedule

Claim 5: “The study, which has not yet been peer-reviewed, had some limitations... As it was retrospective and observational in design”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info

Claim 6: “Compared to the patients taking gliptins, the GLP-1 users were found to have significantly lower progression to stage 4 disease for four types of cancers.”

SINGLE SOURCE

While general evidence confirms GLP-1s manage blood sugar and obesity, the specific finding that GLP-1 users had lower progression to stage 4 disease compared to gliptins is not corroborated by the provided evidence snippets.

travel_explore

web search NEUTRAL — GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists can also help treat obesity.
https://my.clevelandclinic.org/health/treatments/13901-glp-1…

travel_explore

web search NEUTRAL — Mar 18, 2026 · GLP-1 stands for glucagon-like peptide-1, and this is a hormone in the body. When we talk about GLP-1s or GLP-1 agonists as a medication, this means that these are manufactured substanc…
https://mcpress.mayoclinic.org/living-well/are-glp-1s-everyt…

travel_explore

web search NEUTRAL — Apr 6, 2026 · GLP-1 agonist drugs treat diabetes by balancing blood glucose levels. Here’s our list of GLP-1 agonists, how they work, similarities and differences, and more.
https://www.goodrx.com/classes/glp-1-agonists/glp-1-drugs-co…

info

Claim 7: “Three other types of cancer – prostate, pancreatic and kidney – also had lower rates of spread among those taking GLP-1s, but those differences were “not statistically significant,””

SINGLE SOURCE

One source mentions GLP-1s are associated with lower risk for prostate cancer, but the specific detail regarding the lack of statistical significance for prostate, pancreatic, and kidney cancers in this specific study is not corroborated by other provided sources.

travel_explore

web search NEUTRAL — Nov 3, 2025 · GLP-1R agonist use consistently associates with a lower risk for prostate cancer in clinical studies. Multiple recent meta-analyses covering ...
https://pmc.ncbi.nlm.nih.gov/articles/PMC12578377/

travel_explore

web search NEUTRAL — 23 hours ago · A new study revealed that individuals with type 2 diabetes treated with GLP-1 drugs had a significantly lower chance of being diagnosed with 10 ...
https://www.facebook.com/medscape/posts/yet-another-large-da…

travel_explore

web search NEUTRAL — May 21, 2026 · Orland said that no increased risk was observed for adverse events such as pancreatitis, which can be seen with GLP-1 drugs and in cancer ...
https://www.medpagetoday.com/meetingcoverage/asco/121397

info

Claim 8: “the real-world retrospective study included 12,112 patients with the following types of obesity-related cancers, ranging from stage 1 to stage 3: Breast adenocarcinoma, Prostate adenocarcinoma, Non-small cell lung cancer (NSCLC), Colorectal adenocarcinoma, Hepatocellular carcinoma (liver cancer), Renal cell carcinoma, Pancreatic adenocarcinoma”

SINGLE SOURCE

The web results provided for this claim discuss other retrospective studies (e.g., lung cancer in Morocco) but do not mention a study with 12,112 patients covering the specific list of adenocarcinomas mentioned in the claim.

travel_explore

web search NEUTRAL — Methods: A retrospective multicentric observational study was conducted in 6 public hospitals and 6 private centers.Results: The study included 150 patients with mNSCLC from a total of 12 public and p…
https://pubmed.ncbi.nlm.nih.gov/41784605/

travel_explore

web search NEUTRAL — Third, studies that included only patients with T1N0M0 staging showed no significant differences in OS between surgery and SBRT groups, with no heterogeneity among the pooled studies. These findings f…
https://www.scielo.br/j/jbpneu/a/zGJBFKBSHLSwMnvysxNwW6x/?la…

travel_explore

web search NEUTRAL — Non-small cell lung cancer (NSCLC) represents a major global health challenge, primarily due to its frequent diagnosis at advanced stages, which significantly limits therapeutic efficacy and results i…
https://www.researchgate.net/publication/382316335_Machine_L…

check_circle

Claim 9: “The biggest risk reduction was for non-small cell lung cancer (50%), followed by breast cancer (43%), colorectal cancer (31%) and liver cancer (38%).”

CORROBORATED

Multiple sources report the 38% to 50% risk reduction range for the four specific cancers (lung, breast, colorectal, and liver).

menu_book

+ 3 more evidence sources

help

Claim 10: “Overall, patients whose tumors had more of these receptors were about one-third less likely to die during the study period.”

INSUFFICIENT EVIDENCE

No evidence was found in the provided search results to support or refute the claim regarding the 33% lower mortality rate based on receptor levels.

schedule

Claim 11: “The incidence of adverse side effects was similar between GLP-1 and gliptin groups.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

help

Claim 12: “Tumors with higher levels of GLP-1 receptors — proteins that help cells respond to GLP-1 hormones and drugs — were also linked to better survival outcomes”

INSUFFICIENT EVIDENCE

No evidence was found in the provided search results to support or refute the claim regarding GLP-1 receptor levels in tumors.

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.